Zanzalintinib for advanced bladder cancer after previous treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced (spread or cannot be removed by surgery).
- You have had 1 to 3 prior treatments, including a type of immunotherapy (PD-1/PD-L1 inhibitor) and a drug called enfortumab vedotin (unless you could not have them).
- Your cancer has grown despite these treatments.
- You are able to take care of yourself (ECOG performance status 0–2).
- You have not taken a VEGF inhibitor (like sunitinib, pazopanib, or axitinib) before.
- You have adequate organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests a new oral drug, zanzalintinib, for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already been treated with Pluvicto. The goal is to see if this drug can slow the cancer's growth.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.